广州迈普再生医学科技股份有限公司 关于公司股东减持股份计划实施完成的公告 公司股东唐莹女士保证向本公司提供的信息内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 减持股份计划实施完成的公告 证券代码：301033 证券简称：迈普医学 公告编号：2025-083 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 2025 年 10 月 27 日，广州迈普再生医学科技股份有限公司（以 下简称"公司"）收到唐莹女士出具的《关于股份减持计划减持完成 的告知函》，获悉唐莹女士本次减持计划已实施完成，现将本次减持 计划实施进展相关情况公告如下： 一、 股东减持情况 | | | | | | 减持股数 | 减持股数占 | | --- | --- | --- | --- | --- | --- | --- | | 股东名 | 减持方式 | 减持期间 | 减持均价 | 减持股数 | 占公司总 | 公司剔除回 | | 称 | | | （元/股） | （股） | 股本比例 | 购总股本比 | | | | | | | （%） | 例（%） | | 唐莹 | 集中竞价 交易 | 2025 年 7 月 30 ...

Core Viewpoint - The company reported strong financial performance for Q3 2025, with significant year-on-year growth in revenue and net profit, driven by new product launches and strategic acquisitions [1][2]. Financial Performance - For the first three quarters of 2025, the company achieved revenue of 249 million yuan (+30.53%) and a net profit of 76 million yuan (+43.65%) [1]. - In Q3 alone, revenue reached 91 million yuan (+32.74%) and net profit was 29 million yuan (+39.89%) [1]. Product Performance - The company’s various business lines showed steady growth, particularly: 1. The artificial dura mater patch business stabilized after the impact of centralized procurement [2]. 2. PEEK craniofacial repair materials continued to grow steadily, validating the substitution logic for titanium [2]. 3. New products such as absorbable hemostatic gauze and dura mater medical glue experienced rapid growth, significantly contributing to overall revenue [2]. - Gross margin improved to 80.87%, an increase of 2.65 percentage points, primarily due to the higher revenue share from high-margin new products [2]. Strategic Initiatives - The company is actively pursuing strategic acquisitions, including the planned acquisition of 100% of Guangzhou Yijie Medical Technology Co., Ltd., entering the high-potential neurointervention sector [3]. - The acquisition aims to create an integrated solution for brain diseases, potentially unlocking long-term growth opportunities [3]. - The company also announced a partnership to distribute continuous glucose monitoring (CGM) systems, with an estimated procurement amount of 21.5 million yuan, enhancing its product matrix and seeking new growth points [3]. Investment Outlook - The company maintains a "buy" rating, with projected revenues of 374 million yuan, 499 million yuan, and 660 million yuan for 2025-2027, reflecting year-on-year growth rates of 34.5%, 33.3%, and 32.3% respectively [4]. - Expected net profits for the same period are projected at 110 million yuan, 157 million yuan, and 230 million yuan, with corresponding EPS of 1.64, 2.34, and 3.43 yuan [4].

Investment Rating - The report maintains a "Buy" rating for the company [7] Core Views - The company has demonstrated strong revenue growth, with a 30.53% increase in revenue to 249 million yuan and a 43.65% increase in net profit to 76 million yuan for the first three quarters of 2025 [6] - New products are driving growth both domestically and internationally, particularly the absorbable hemostatic gauze and dura mater medical glue, which have seen rapid market expansion [6] - The acquisition of Easy Medical Technology positions the company in the high-potential neuro-intervention sector, creating a comprehensive solution for brain diseases and potentially unlocking long-term growth [7] Financial Performance Summary - For the first three quarters of 2025, the company achieved revenue of 249 million yuan (+30.53%) and net profit of 76 million yuan (+43.65%) [6] - The gross margin improved to 80.87%, an increase of 2.65 percentage points, driven by the higher revenue share from new high-margin products [6] - Forecasted revenues for 2025-2027 are expected to be 374 million yuan, 499 million yuan, and 660 million yuan, representing year-on-year growth rates of 34.5%, 33.3%, and 32.3% respectively [7][11] Strategic Developments - The company is actively pursuing strategic acquisitions and partnerships to enhance its product offerings and market reach, including the acquisition of Easy Medical Technology [7] - The company plans to expand its product matrix by including continuous glucose monitoring systems, with an estimated procurement amount of 21.5 million yuan [7]

归属结果暨股份上市的公告 证券代码：301033 证券简称：迈普医学 公告编号：2025-082 广州迈普再生医学科技股份有限公司 关于 2024 年限制性股票激励计划首次授予第一个归属期 归属结果暨股份上市的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1、本次归属的限制性股票上市流通日：2025 年 10 月 27 日，本 次归属的第二类限制性股票不设限售期； 2、本次办理归属的限制性股票数量为 110,717 股，占公司总股 本（剔除回购股份，下同）0.17%； 3、本次归属的激励对象人数：26 人； 4、本次归属的限制性股票来源为公司从二级市场回购的本公司 人民币 A 股普通股股票。 广州迈普再生医学科技股份有限公司（以下简称"公司"）于 2025 年 8 月 28 日召开了第三届董事会第十四次会议，审议通过了《关 于 2024 年限制性股票激励计划首次授予部分第一个归属期归属条件 成就的议案》，董事会认为，公司 2024 年限制性股票激励计划（以 下简称"《激励计划》"、"本激励计划"）首次授予部分第一个归 本激励计划拟授予激 ...

Summary of Maipu Medical's Conference Call Company Overview - **Company**: Maipu Medical - **Industry**: Medical Devices Key Points and Arguments Financial Performance - **Net Profit Growth**: The company's net profit after deducting non-recurring items increased by 57.94% year-on-year, indicating strong financial health and operational efficiency [2][3][8] - **Revenue Growth**: In Q3 2025, Maipu Medical achieved a revenue of 249 million yuan, a year-on-year increase of 30.53% [3] - **Gross Margin**: The gross margin improved to 80.87% in Q3 2025, attributed to stable margins from existing products, increased revenue from new products, and enhanced production efficiency [2][8] Product Development and Market Expansion - **New Product Launches**: The company has made significant progress in channel development for new products, particularly two newly launched products expected to drive future growth [2][3] - **Product Line Expansion**: Maipu Medical plans to enrich its product line through acquisitions, focusing on becoming a provider of comprehensive solutions for elderly diseases, including brain vascular diseases and brain tumors [2][7] - **International Market Strategy**: The company aims to increase its overseas revenue share to over 25% in the next 3-5 years, with a focus on expanding its international sales team and product registrations [3][19] Strategic Initiatives - **Collective Procurement Impact**: The collective procurement results for hemostatic materials are expected by December 2025, which could significantly enhance market share for hemostatic gauze [2][5] - **Acquisition Plans**: There are no immediate plans for acquisitions related to associated companies, but the company is actively exploring partnerships to enhance its product matrix [2][4] Operational Insights - **Sales and Marketing Expenses**: Sales expenses have increased due to team expansion and new product promotions, totaling over 40 million yuan in the first three quarters of 2025 [12] - **Clinical Trials and Certifications**: The hemostatic gauze is expected to receive new certification by the end of 2025, allowing for competition with major players like Johnson & Johnson in the international market [15] Competitive Landscape - **Market Positioning**: Maipu Medical's hemostatic gauze is positioned as a high-end product with superior performance compared to competitors, aiming to capture significant market share in challenging surgical scenarios [18] Future Outlook - **Revenue Projections**: The company anticipates a significant increase in international sales capabilities and channel management by mid to late 2026, with expectations of improved overall business performance [19] - **Product Development Timeline**: Hemostatic powder is in clinical stages, with expectations for market entry by late 2026 or early 2027, while hemostatic gel is projected for launch by late 2027 or early 2028 [25] Additional Important Information - **Team Expansion**: The international team has grown from 8 to 18 members to support new product launches and market penetration [23][24] - **Market Dynamics**: The collective procurement process typically influences distributor purchasing behavior for about one quarter, but demand for surgical products remains stable [26]

Group 1: Company Overview and Performance - Guangzhou Maipu Regenerative Medicine Technology Co., Ltd. specializes in high-performance medical devices, particularly in the neurosurgery field, offering key implantable medical devices for craniotomy surgeries [3][4]. - As of September 30, 2025, the company achieved a revenue of CNY 24,922.82 million, representing a year-on-year growth of 30.53% [4]. - The net profit attributable to shareholders reached CNY 7,585.40 million, marking a 43.65% increase compared to the previous year [4]. Group 2: Strategic Initiatives - The company is focusing on both internal growth and external expansion by diversifying its product matrix, including the introduction of blood glucose and minimally invasive products [5]. - This strategy aims to enhance the company's comprehensive service capabilities and customer loyalty while contributing to new revenue and profit growth [5]. Group 3: Market and Product Insights - The company is actively participating in the collective procurement of hemostatic materials, with a focus on the opportunities presented by national and local procurement policies [6]. - The acquisition target "Yijie Medical" specializes in providing minimally invasive solutions for cerebrovascular diseases, indicating a strategic move to expand its product offerings in the neurosurgery sector [6]. Group 4: International Market Performance - The company has a presence in over 100 countries and regions, with Europe contributing the largest share of overseas revenue [8]. - The artificial dura (spinal) membrane patch is the top contributor to overseas revenue during the reporting period [8]. Group 5: Research and Development - The absorbable regenerated oxidized cellulose hemostatic granules are currently in the clinical trial phase, achieving significant progress [8]. - The company is also planning to expand the indications for its already marketed dura mater medical glue product [8].

Core Viewpoint - Maipu Medical announced the convening of its board meeting to review the Q3 2025 report, indicating ongoing corporate governance and financial oversight [1] Company Summary - Maipu Medical's revenue composition for the year 2024 is as follows: 97.51% from implantable medical devices and 2.49% from other sources, highlighting a strong focus on its core product line [1] - As of the latest update, Maipu Medical has a market capitalization of 4.7 billion yuan, reflecting its position in the market [1] Industry Summary - The Chinese innovative drug sector has seen significant overseas licensing deals, totaling 80 billion USD this year, indicating a robust international interest in Chinese biopharmaceuticals [1] - Despite the hot secondary market for biomedicine, the primary market is experiencing a cooling in fundraising, suggesting a divergence in market dynamics [1]

Group 1 - The core viewpoint of the article highlights the strong financial performance of MaiPu Medical in the third quarter, with significant year-on-year growth in both revenue and net profit [1] Group 2 - The company reported a total operating revenue of 249 million yuan for the first three quarters, representing a year-on-year increase of 30.53% [1] - The net profit attributable to shareholders of the listed company reached 75.85 million yuan, reflecting a year-on-year growth of 43.65% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 72.79 million yuan, showing a year-on-year increase of 57.94% [1]

Major Events - Former Chairman of Beiyin Wealth Management, Fang Yi, has joined Huaxia Bank as Chief Risk Officer, pending regulatory approval [4] - Xilai Materials' subsidiary plans to invest 2 billion yuan in a semiconductor core component project, expected to generate over 1.5 billion yuan in annual output after reaching production [5][6] - Huatai Securities' subsidiary Huatai Futures has appointed Zhao Changtao as the new chairman [7] - Chuanfa Longmang's subsidiary plans to invest 366 million yuan in a 100,000 tons/year lithium dihydrogen phosphate project [8] - Huagong Technology is planning to issue H-shares and apply for listing on the Hong Kong Stock Exchange [9] - Jiangsu Leili's actual controller has changed from Su Jianguo to both Su Jianguo and Su Da due to internal share transfers [10] - Electric Power Investment Energy has been unable to contact independent director Han Fang, but this does not affect the board's operation [11] - Qiaqia Food's subsidiary is establishing an investment company focused on the leisure food industry with a total investment of 4 billion yuan [12][13] - Steel Research High-tech plans to set up a wholly-owned subsidiary in Saudi Arabia with an investment of up to 138 million yuan [14] - Yangjie Technology has terminated the acquisition of 100% equity in Better Electronics due to differences in business types and management [15] Performance Reports - Youfa Group reported a 2320.53% increase in net profit for Q3, despite a 3.97% decline in revenue [16] - Zhuoyi Information's net profit increased by 2074.65% in Q3, with revenue growth of 2.52% [17] - North Navigation's Q3 net profit surged by 1681.27%, with a 52.12% increase in revenue [18] - Tianneng Heavy Industry's net profit grew by 1359.03% in Q3, driven by increased sales of tower tubes [19] - Te Yi Pharmaceutical's net profit rose by 985.18% in Q3, with significant growth in traditional Chinese medicine sales [20] - Hualgreen Bio's Q3 net profit increased by 619.37%, with a 35.24% rise in revenue [21] - Zhenlei Technology's net profit grew by 598.09% in Q3, supported by strong revenue growth [22] - Shengyi Electronics expects a net profit increase of 476% to 519% for the first three quarters of 2025 [23] - Glodon reported a 244.89% increase in Q3 net profit, despite a slight decline in revenue [24] - Yingli Co., Ltd. saw a 229.14% increase in Q3 net profit, with a 14.73% rise in revenue [25] - Guangkang Biochemical's Q3 net profit increased by 236.87%, despite a decline in revenue [26] - High-speed Electric's Q3 net profit rose by 242.35%, with a 44.51% increase in revenue [27] - Wide Special Materials reported a 213.65% increase in net profit for Q3, driven by improved gross margins [28] - Baofeng Energy's Q3 net profit increased by 162.34%, attributed to increased production capacity [29] - Sanfu Co., Ltd. reported a 162.25% increase in Q3 net profit, driven by improved profitability of potassium and silane products [30] - Wuku New Energy's Q3 net profit increased by 106.31%, despite a loss in the first three quarters [32] - Pioneering Technology's Q3 net profit grew by 94.01%, supported by a recovery in the household energy storage market [33] - Sanlife Guojian's net profit increased by 71.15% in Q3, driven by project collaboration and CDMO business growth [34] - BGI Genomics reported a loss of 120 million yuan in the first three quarters, despite revenue growth [35] - Rejing Bio reported a net loss of 10.9 million yuan in the first three quarters, impacted by industry policies [36] - Jiangshan Oupai reported a net loss of 51.58 million yuan in Q3, attributed to market downturns and increased competition [38] - Taiping Bird reported a net loss of 49.45 million yuan in Q3, due to declining revenue and increased inventory losses [39] - Zhongke Tongda reported a loss of 6.87 million yuan in the first three quarters, affected by project delays and market competition [40] - Wolong New Energy reported a loss of 579.7 thousand yuan in Q3, transitioning from profit to loss [41] Major Contracts - Jinggong Steel Structure signed a significant overseas project contract worth approximately 1.23 billion yuan [42][43] - New Beiyang's subsidiary won a 105 million yuan postal equipment outsourcing project [44] - Maipu Medical plans to sign product sales agency agreements with related parties, with estimated procurement amounts of 21.5 million yuan and 3.5 million yuan [45] Shareholding Changes - Yunlu Co., Ltd. shareholder Guo Keyun plans to reduce his stake by up to 3% [46] Financing - Xinda Securities has received approval from the CSRC to issue up to 10 billion yuan in technology innovation corporate bonds [47]

智通财经APP讯，迈普医学(301033.SZ)发布2025年三季度报告，该公司前三季度营业收入为2.49亿元， 同比增长30.53%。归属于上市公司股东的净利润为7585.4万元，同比增长43.65%。归属于上市公司股东 的扣除非经常性损益的净利润为7279.19万元，同比增长57.94%。基本每股收益为1.15元。 ...